ReviewCureus2026
Ocular and Orbital Involvement in Extranodal Natural Killer/T-cell Lymphoma: A Systematic Review of Clinical Outcomes and Prognostic Factors.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare and aggressive malignancy, with ocular and orbital involvement representing an uncommon but clinically important presentation. Many cases are frequently misdiagnosed due to their ability to mimic common inflammatory and infectious eye conditions, resulting in delayed diagnosis and poorer clinical outcomes. This systematic review aimed to evaluate clinical outcomes and prognostic factors in ocular and orbital ENKTL. A PRISMA-compliant systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261348194) and conducted using PubMed, MEDLINE, Embase, and Cochrane Library from database inception to 19 March 2026. Twenty-eight studies comprising approximately 429 patients were included. Data were extracted on patient demographics, treatment, survival, and prognostic factors, and analysed using a narrative synthesis. Median survival ranged from six to 17 months, with high mortality and frequent reports of rapid clinical deterioration. Delayed diagnosis, advanced disease, central nervous system involvement, and relapse were associated with poorer outcomes. Non-anthracycline, asparaginase-based regimens were associated with improved disease control compared with conventional therapies, although outcomes remained poor overall. Visual outcomes were similarly unfavourable. Improved survival was associated with early recognition, prompt biopsy, and timely initiation of appropriate treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.